packageRelugolix

relugolix

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Relugolix is a hormone antagonist used in the treatment of prostate cancer. It is an approved medicine, with one product authorised in the European Union for prostatic tumours.

Summary written by glm-5.3-flash from Wikidata Q21099000 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:relugolix
ATC codes:L02BX04
DrugBank:DB11853
PubChem CID:10348973
Wikidata:Q21099000
formula:C29H27F2N7O5S
molar mass:623.635 g/mol (PubChem CID 10348973)
logP:3.2 (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown